论文部分内容阅读
1.3—6月针剂孕激素酯的合成世界卫生组织人类生殖研究特别规划(HRP)协调合成的两种左旋十八甲基炔诺酮酯己在伦敦和墨西哥城的合作中心进行药物动力学和药效学的研究。根据已获得的研究结果,可望在最近选出一种酯作为进一步研制的对象。由于该药可能用于男性或女性避孕方法,目前HRP 已在美国和其他国家申请专利。2.每月针剂据中国、印度和墨荫哥等国的研究报告:每月针剂同2～3月针剂相比,使用者出血图象较好,月经也较稳定。几年来HRP 参于研制和改善这类针剂,力争在1985年末向社会提供这种新型避孕方法。
January 3-6 Progestogen Ester Synthesis The two levo-norgestrel esters developed in collaboration with the Human Reproductive Research Special Program (HRP) of the World Health Organization (WHO) collaborated at the Collaborating Centers in London and Mexico for pharmacokinetics and pharmacology Efficacy research. Based on the results obtained, it is expected that an ester will be selected recently for further development. Since this medicine may be used in male or female contraception, HRP is currently patentable in the United States and other countries. 2 monthly injection According to China, India and Mexico Yin brother and other countries report: monthly injection with 2 to 3 months compared to injection, the user better bleeding images, menstruation is also more stable. For several years HRP has been involved in the development and improvement of such injections and strives to provide this new type of contraceptive method to the community by the end of 1985.